Pharmacologic DNA demethylation of ALCL cell lines without DUSP22 rearrangement recapitulates the overexpression of cancer-testing antigens and other DUSP22 signature genes, suggesting that demethylating agents might reprogram aggressive subtypes of ALK- ALCL into a “DUSP22-like immunogenic molecular signature” with a potential impact on prognosis [70]. The gene discussed is DUSP22; the disease is anaplastic large cell lymphoma.